Dr. Now, of TLC fame, will help 10 individuals who each weigh over 600 pounds as they pursue life-altering bariatric surgery.

The 6,000 LB Diaries with Dr. Now promises a raw and emotional look into the lives of people facing the challenges of extreme weight loss and thus inspiring many to walk the path to stay fit.

But you can forgive him for thinking that it was longer. During his travels, the professional cyclist braved brutal headwinds, extreme temperatures, dangerous traffic and even dusted himself off ...

Copyright 2025 The Associated Press. All Rights Reserved. Remnants of a bathroom that fell off the wharf are visible at the mouth of the San Lorenzo River in Santa ...

In a first, scientists at the World Health Organisation (WHO) have endorsed a new class of medicines known as GLP-1 receptor agonists, which mimic a hormone that regulates appetite and blood sugar ...

Novo Nordisk shares fell sharply on Friday as disappointing results from tests of its latest obesity drug wiped about €90 billion off the valuation of Europe’s largest company by market ...

In a study, people who took Zepbound had fewer breathing interruptions. The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...

And while I may sound like a broken record, I want to stress again that the pace of innovation in the obesity market is unlike anything we have seen in drug development. I expect Novo Nordisk to ...

LONDON/COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

The numbers showed that both average body mass index (BMI) and obesity rates across the population fell in 2023, having risen steadily since 2013 before leveling in 2022. While we don't yet have any ...

A new type of obesity drug being developed by Novo Nordisk has fallen short of expectations set by the company in a closely watched Phase 3 trial, causing shares to lose nearly a fifth of their value ...

(AP Photo/Patrick Sison, File) WASHINGTON (AP) — Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and diabetes will need to phase ...